Hirsutanol A inhibits T‑acute lymphocytic leukemia Jurkat cell viability through cell cycle arrest and p53‑dependent induction of apoptosis

Zhong,Fangfang; Yang,You; Ren,Danwei; Long,Sili; Qin,Xiang; Liu,Jing; Zeng,Yan; Lan,Wenjian; Ma,Wenzhe; Liu,Wenjun

doi:10.3892/etm.2021.10173

Hirsutanol A inhibits T‑acute lymphocytic leukemia Jurkat cell viability through cell cycle arrest and p53‑dependent induction of apoptosis

Authors:
- Fangfang Zhong
- You Yang
- Danwei Ren
- Sili Long
- Xiang Qin
- Jing Liu
- Yan Zeng
- Wenjian Lan
- Wenzhe Ma
- Wenjun Liu
View Affiliations

Affiliations: State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau 999078, Macau SAR, P.R. China, Department of Pediatrics, Affiliated Hospital of Southwest Medical University, Sichuan Clinical Research Center for Birth Defects, Luzhou, Sichuan 646000, P.R. China, School of Pharmaceutical Sciences, Sun Yat‑sen University, Guangzhou, Guangdong 510006, P.R. China
Published online on: May 11, 2021 https://doi.org/10.3892/etm.2021.10173
Article Number: 741
Copyright: © Zhong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute lymphocytic leukemia (ALL) is a type of childhood leukemia with the highest incidence; T‑acute lymphocytic leukemia (T‑ALL) is far more difficult to treat than B‑acute lymphocytic leukemia (B‑ALL) and has a poor long‑term prognosis. Therefore, there is an urgent requirement to develop effective drugs for the treatment of T‑ALL. Hirsutanol A is a natural sesquiterpenoid compound. The aim of the present study was to evaluate the in vitro anticancer activity of hirsutanol A against T‑acute lymphocytic leukemia Jurkat cells and investigate the mechanism of action. A Cell Counting Kit‑8 assay demonstrated that hirsutanol A inhibited the viability of Jurkat cells in a dose‑ and time‑dependent manner. In addition, hirsutanol A induced cell cycle arrest at the G2 phase as determined via flow cytometry. Furthermore, Hoechst staining, Annexin V‑FITC/propidium iodide double staining, mitochondrial membrane potential detection using JC‑1 and western blot analysis of apoptotic proteins indicated that the inhibitory effect of hirsutanol A on Jurkat cells was associated with the induction of apoptosis. Of note, hirsutanol A induced the expression of the tumor suppressor p53, whereas simultaneous treatment with pifithrin‑α, an inhibitor of p53, significantly reduced Jurkat cell apoptosis induced by hirsutanol A. In summary, the present study suggested that hirsutanol A inhibited Jurkat cell viability through induction of cell cycle arrest and p53‑dependent initiation of apoptosis, thus hirsutanol may serve as a promising compound for the treatment of T‑ALL.

View Figures

View References

1	Gao J and Liu WJ: Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: A meta-analysis. Eur Rev Med Pharmacol Sci. 22:7858–7866. 2018.PubMed/NCBI View Article : Google Scholar
2	Terwilliger T and Abdul-Hay M: Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer J. 7(e577)2017.PubMed/NCBI View Article : Google Scholar
3	Papadantonakis N and Advani AS: Recent advances and novel treatment paradigms in acute lymphocytic leukemia. Ther Adv Hematol. 7:252–269. 2016.PubMed/NCBI View Article : Google Scholar
4	Matloub Y, Stork L, Asselin B, Hunger SP, Borowitz M, Jones T, Bostrom B, Gastier-Foster JM, Heerema NA, Carroll A, et al: Outcome of children with standard-risk T-lineage acute lymphoblastic leukemia-comparison among different treatment strategies. Pediatr Blood Cancer. 63:255–261. 2016.PubMed/NCBI View Article : Google Scholar
5	Qin X, Zhang MY and Liu WJ: Application of minimal residual disease monitoring in pediatric patients with acute lymphoblastic leukemia. Eur Rev Med Pharmacol Sci. 22:6885–6895. 2018.PubMed/NCBI View Article : Google Scholar
6	Wang M, Wen J, Guo Y, Shen Y, An X, Hu Y and Xiao J: Clinical characterization and prognosis of T cell acute lymphoblastic leukemia with high CRLF2 gene expression in Children. PLoS One. 14(e0224652)2019.PubMed/NCBI View Article : Google Scholar
7	Takahashi H, Kajiwara R, Kato M, Hasegawa D, Tomizawa D, Noguchi Y, Koike K, Toyama D, Yabe H, Kajiwara M, et al: Treatment outcome of children with acute lymphoblastic leukemia: The Tokyo Children's Cancer Study Group (TCCSG) Study L04-16. Int J Hematol. 108:98–108. 2018.PubMed/NCBI View Article : Google Scholar
8	Li Y, Buijs-Gladdines JG, Canté-Barrett K, Stubbs AP, Vroegindeweij EM, Smits WK, van Marion R, Dinjens WN, Horstmann M, Kuiper RP, et al: IL-7 receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: A genome sequencing study. PLoS Med. 13(e1002200)2016.PubMed/NCBI View Article : Google Scholar
9	Raetz EA and Teachey DT: T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016:580–588. 2016.PubMed/NCBI View Article : Google Scholar
10	Punzo F, Manzo I, Tortora C, Pota E, Angelo V, Bellini G, Di Paola A, Verace F, Casale F and Rossi F: Effects of CB2 and TRPV1 receptors' stimulation in pediatric acute T-lymphoblastic leukemia. Oncotarget. 9:21244–21258. 2018.PubMed/NCBI View Article : Google Scholar
11	Tosello V and Ferrando A: The NOTCH signaling pathway: Role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther Adv Hematol. 4:199–210. 2013.PubMed/NCBI View Article : Google Scholar
12	Juliusson G and Hough R: Leukemia. Prog Tumor Res. 43:87–100. 2016.PubMed/NCBI View Article : Google Scholar
13	Tan SH, Bertulfo FC and Sanda T: Leukemia-initiating cells in T-cell acute lymphoblastic leukemia. Front Oncol. 7(218)2017.PubMed/NCBI View Article : Google Scholar
14	Rose-Inman H and Kuehl D: Acute leukemia. Hematol Oncol Clin North Am. 31:1011–1028. 2017.PubMed/NCBI View Article : Google Scholar
15	Kuhlen M, Klusmann JH and Hoell JI: Molecular approaches to treating pediatric leukemias. Front Pediatr. 7(368)2019.PubMed/NCBI View Article : Google Scholar
16	Wang Y, Chen H and Chen J: The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Lett. 438:63–75. 2018.PubMed/NCBI View Article : Google Scholar
17	Peters C, Cornish JM, Parikh SH and Kurtzberg J: Stem cell source and outcome after hematopoietic stem cell transplantation (HSCT) in children and adolescents with acute leukemia. Pediatr Clin North Am. 57:27–46. 2010.PubMed/NCBI View Article : Google Scholar
18	Wang GYS, Abrell LM, Avelar A, Borgeson BM and Crews P: New hirsutane based sesquiterpenes from salt water cultures of a marine sponge-derived fungus and the terrestrial fungus Coriolus consors. Tetrahedron. 26:7335–7342. 1998.
19	Li HJ, Lan WJ, Lam CK, Yang F and Zhu XF: Hirsutane sesquiterpenoids from the marine-derived fungus Chondrostereum sp. Chem Biodivers. 8:317–324. 2011.PubMed/NCBI View Article : Google Scholar
20	Yang F, Chen WD, Deng R, Li DD, Wu KW, Feng GK, Li HJ and Zhu XF: Hirsutanol A induces apoptosis and autophagy via reactive oxygen species accumulation in breast cancer MCF-7 cells. J Pharmacol Sci. 119:214–220. 2012.PubMed/NCBI View Article : Google Scholar
21	Wenzel ES and Singh ATK: Cell-cycle checkpoints and aneuploidy on the path to cancer. In Vivo. 32:1–5. 2018.PubMed/NCBI View Article : Google Scholar
22	Wang Y, Zhong J, Bai J, Tong R, An F, Jiao P, He L, Zeng D, Long E, Yan J, et al: The application of natural products in cancer therapy by targeting apoptosis pathways. Curr Drug Metab. 19:739–749. 2018.PubMed/NCBI View Article : Google Scholar
23	Green DR and Reed JC: Mitochondria and apoptosis. Science. 281:1309–1312. 1998.PubMed/NCBI View Article : Google Scholar
24	Sinha K, Das J, Pal PB and Sil PC: Oxidative stress: The mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol. 87:1157–1180. 2013.PubMed/NCBI View Article : Google Scholar
25	Julien O and Wells JA: Caspases and their substrates. Cell Death Differ. 24:1380–1389. 2017.PubMed/NCBI View Article : Google Scholar
26	Ranjan A and Iwakuma T: Non-canonical cell death induced by p53. Int J Mol Sci. 17(2068)2016.PubMed/NCBI View Article : Google Scholar
27	Abdelmabood S, Fouda AE, Boujettif F and Mansour A: Treatment outcomes of children with acute lymphoblastic leukemia in a middle-income developing country: High mortalities, early relapses, and poor survival. J Pediatr (Rio J). 96:108–116. 2020.PubMed/NCBI View Article : Google Scholar
28	Khalifa SAM, Elias N, Farag MA, Chen L, Saeed A, Hegazy MF, Moustafa MS, Abd El-Wahed A, Al-Mousawi SM, Musharraf SG, et al: Marine natural products: A source of novel anticancer drugs. Mar Drugs. 17(491)2019.PubMed/NCBI View Article : Google Scholar
29	Yang F, Gao YH, Wu KW, Deng R, Li DD, Wei ZX, Jiang S, Wu XQ, Feng GK, Li HJ and Zhu XF: A novel sesquiterpene Hirsutanol A induces autophagical cell death in human hepatocellular carcinoma cells by increasing reactive oxygen species. Chin J Cancer. 29:655–660. 2010.PubMed/NCBI View Article : Google Scholar
30	Yang F, Chen WD, Deng R, Zhang H, Tang J, Wu KW, Li DD, Feng GK, Lan WJ, Li HJ and Zhu XF: Hirsutanol A, a novel sesquiterpene compound from fungus Chondrostereum sp., induces apoptosis and inhibits tumor growth through mitochondrial-independent ROS production: Hirsutanol A inhibits tumor growth through ROS production. J Transl Med. 11(32)2013.PubMed/NCBI View Article : Google Scholar
31	Li HJ, Jiang WH, Liang WL, Huang JX, Mo YF, Ding YQ, Lam CK, Qian XJ, Zhu XF and Lan WJ: Induced marine fungus Chondrostereum sp. as a means of producing new sesquiterpenoids chondrosterins I and J by using glycerol as the carbon source. Mar Drugs. 12:167–175. 2014.PubMed/NCBI View Article : Google Scholar
32	Correia C, Lee SH, Meng XW, Vincelette ND, Knorr KL, Ding H, Nowakowski GS, Dai H and Kaufmann SH: Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta. 1853:1658–1671. 2015.PubMed/NCBI View Article : Google Scholar
33	Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.PubMed/NCBI View Article : Google Scholar
34	Wang Y, Liu C, Wang J, Zhang Y and Chen L: Iodine-131 induces apoptosis in human cardiac muscle cells through the p53/Bax/caspase-3 and PIDD/caspase-2/t-BID/cytochrome c/caspase-3 signaling pathway. Oncol Rep. 38:1579–1586. 2017.PubMed/NCBI View Article : Google Scholar
35	Burke PJ: Mitochondria, bioenergetics and apoptosis in cancer. Trends Cancer. 3:857–870. 2017.PubMed/NCBI View Article : Google Scholar
36	Tichy A, Marek J, Havelek R, Pejchal J, Seifrtova M, Zarybnicka L, Filipova A, Rezacova M and Sinkorova Z: New light on an old friend: Targeting PUMA in radioprotection and therapy of cardiovascular and neurodegenerative diseases. Curr Drug Targets. 19:1943–1957. 2018.PubMed/NCBI View Article : Google Scholar
37	Vávrová J and Rezáčová M: Importance of proapoptotic protein PUMA in cell radioresistance. Folia Biol (Praha). 60:53–56. 2014.PubMed/NCBI
38	Hickman ES, Moroni MC and Helin K: The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev. 12:60–66. 2002.PubMed/NCBI View Article : Google Scholar
39	Brázda V and Fojta M: The rich world of p53 DNA binding targets: The role of DNA structure. Int J Mol Sci. 20(5605)2019.PubMed/NCBI View Article : Google Scholar
40	Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 9:402–412. 2008.PubMed/NCBI View Article : Google Scholar
41	Matt S and Hofmann TG: The DNA damage-induced cell death response: A roadmap to kill cancer cells. Cell Mol Life Sci. 73:2829–2850. 2016.PubMed/NCBI View Article : Google Scholar